強皮症の世界市場レポート 2025年

強皮症の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.9％で32億5,000万米ドルに成長します。予測期間の成長は、生物学的療法、精密医療、幹細胞療法、ゲノムおよびバイオマーカー研究、世界な共同研究に起因しています。予測期間における主な動向には、デジタルヘルスソリューション、マイクロバイオームへの注目、患者中心のケア、再生医療、健康の公平性とアクセスなどがあります。

強皮症の普及率が高まっていることが、今後の強皮症市場の成長を後押ししています。強皮症は、皮膚やその他の組織に構造を提供するタンパク質であるコラーゲンの異常増殖を特徴とする慢性自己免疫疾患です。この疾患は、様々な環境要因によって引き起こされる可能性のある、制御不能な免疫反応によって開発されます。症例数の増加に伴い、診断と治療の改善の必要性が明らかになっています。強皮症治療薬は、免疫反応を調節し、環境リスク因子への曝露を減らすことにより、疾患の管理と症状の緩和に重要な役割を果たしています。例えば、2022年6月、スイスを拠点とする査読付き学術誌の出版社であるKarger Publishers社は、強皮症患者は英国に19,000人、世界に250万人いると報告しました。さらに、2024年8月、英国を拠点とするオックスフォード大学付属の大学出版社Oxford Academic Pressが発表した調査論文では、CPRDに登録された1,010万人のうち1,588例が全身性硬化症（SSc）であることが確認され、その結果、主に粘膜がん（4.5％）、肺がん（2.1％）、乳がん（1.9％）を含む206のがんと診断されました。したがって、強皮症の有病率の上昇が強皮症市場を牽引しています。

毒素への暴露が強皮症市場の成長を促進しています。毒素への暴露とは、生体システムに悪影響を与える有害物質との接触や摂取を指します。強皮症市場は、環境および遺伝的誘因の可能性がある強皮症に罹患した人々のための研究促進、標的治療開発、患者ケアの改善を通じて、この問題に対処する上で重要な役割を果たしています。例えば、2024年4月、英国の環境・食糧・農村地域省（Department for Environment, Food, and Rural Affairs）が公表したデータによると、都市部のバックグラウンド濃度は2022年から3％上昇し、2023年には66.8μg/m3に達し、これは時系列で記録された最高値です。したがって、有害物質への暴露が強皮症市場を前進させています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の強皮症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の強皮症市場：成長率分析
• 世界の強皮症市場の実績：規模と成長, 2019-2024
• 世界の強皮症市場の予測：規模と成長, 2024-2029, 2034F
• 世界の強皮症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の強皮症市場：治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 医薬品
• 手術
• その他の治療
• 世界の強皮症市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 体系的な強皮症
• ローカライズ強皮症
• 世界の強皮症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 医薬品店
• その他のエンドユーザー
• 世界の強皮症市場：医薬品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫抑制剤
• 抗線維化剤
• 血管拡張薬
• コルチコステロイド
• 鎮痛剤
• 世界の強皮症市場：手術のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肺移植
• その他の外科的介入
• 世界の強皮症市場：その他の治療のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 理学療法
• 作業療法
• ライフスタイルの変更
• 代替療法

第7章 地域別・国別分析

• 世界の強皮症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の強皮症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 強皮症市場：競合情勢
• 強皮症市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson And Johnson Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Merck And Co. Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• GSK plc
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Aspen Pharmacare Holdings Limited
• Boehringer Ingelheim International GmbH
• Principia Biopharma Corp

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 強皮症市場2029：新たな機会を提供する国
• 強皮症市場2029：新たな機会を提供するセグメント
• 強皮症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Scleroderma is an uncommon autoimmune disease characterized by the chronic and rare abnormal growth of collagen, a protein responsible for forming the structural framework of the skin and other tissues. Various treatments aim to address the excessive production of collagen, either providing cures, halting its overproduction, effectively managing associated symptoms, or reducing the risk of complications linked to scleroderma.

The primary treatments for scleroderma encompass medication, surgery, and other therapeutic approaches. Medication involves the use of substances, typically in the form of drugs or pharmaceuticals, intended to prevent, treat, or manage medical conditions, diseases, or symptoms. Hospitals, pharmaceutical stores, and other healthcare providers commonly administer medications, specifically indicated for treating both systemic scleroderma and localized scleroderma.

The scleroderma market research report is one of a series of new reports from The Business Research Company that provides scleroderma market statistics, including scleroderma industry global market size, regional shares, competitors with a scleroderma market share, detailed scleroderma market segments, market trends and opportunities, and any further data you may need to thrive in the scleroderma industry. This scleroderma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The scleroderma market size has grown strongly in recent years. It will grow from $2.33 billion in 2024 to $2.49 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to advances in diagnosis, immunological research, therapeutic developments, awareness and education, genetic studies

The scleroderma market size is expected to see strong growth in the next few years. It will grow to $3.25 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to biological therapies, precision medicine, stem cell therapies, genomic and biomarker research, global collaborations. Major trends in the forecast period include digital health solutions, focus on microbiome, patient-centric care, regenerative medicine, health equity and access.

The increasing prevalence of scleroderma is driving the growth of the scleroderma market in the future. Scleroderma is a chronic autoimmune disease characterized by the abnormal growth of collagen, a protein that provides structure to the skin and other tissues. This condition develops due to an unregulated immune response, potentially triggered by various environmental factors. As the number of cases grows, the need for improved diagnosis and treatment becomes clear. Scleroderma therapeutics play a crucial role in managing the disease and alleviating symptoms by regulating the immune response and reducing exposure to environmental risk factors. For instance, in June 2022, Karger Publishers, a Switzerland-based publisher of peer-reviewed journals, reported that there were 19,000 people with scleroderma in the UK and 2.5 million worldwide. Additionally, in August 2024, a research article published by Oxford Academic Press, a UK-based university press affiliated with the University of Oxford, identified 1,588 cases of systemic sclerosis (SSc) among 10.1 million individuals in the CPRD, resulting in the diagnosis of 206 cancers, primarily mucocutaneous (4.5%), lung (2.1%), and breast (1.9%). Therefore, the rising prevalence of scleroderma is driving the scleroderma market.

The exposure to toxins is advancing the growth of the scleroderma market. Exposure to toxins refers to the contact with or ingestion of harmful substances that can negatively impact biological systems. The scleroderma market plays a crucial role in addressing this issue by promoting research, developing targeted therapies, and improving patient care for those affected by scleroderma, a condition with possible environmental and genetic triggers. For instance, in April 2024, data published by the Department for Environment, Food, and Rural Affairs, a UK-based ministerial department, indicated that urban background concentrations increased by 3 percent from 2022, reaching 66.8 µg/m3 in 2023, which is the highest value recorded in the time series. Therefore, exposure to toxins is driving the scleroderma market forward.

The development of novel treatments is a prominent trend gaining traction in the scleroderma market. Leading companies in the market are actively engaged in creating innovative drugs to effectively manage symptoms and maintain their market position. For example, in April 2022, Tyr Pharma Inc., a biotherapeutics manufacturer based in the US, secured regulatory approval from the US Food and Drug Administration for its groundbreaking systemic sclerosis-related interstitial lung disease drug, efzofitimod. This First-in-class immunomodulator targets the neuropilin-2 (NRP2) receptor to downregulate and control the immune response, offering relief from scleroderma symptoms. Moreover, efzofitimod demonstrated efficacy in reducing pro-inflammatory markers in a clinical study involving patients with pulmonary sarcoidosis, further highlighting its potential impact.

Major companies operating in the scleroderma market are emphasizing product launches, including a clinical trial platform, to advance scleroderma treatments and identify promising agents for progression from Phase IIb to Phase III. A clinical trial platform serves as a comprehensive infrastructure facilitating the concurrent assessment of multiple therapies across various clinical trials. In August 2023, The Scleroderma Research Foundation (SRF), a non-profit organization based in the US, introduced CONQUEST, a groundbreaking clinical trial platform. With a global reach spanning 130 centers in 22 countries, CONQUEST employs a master protocol to evaluate multiple therapies simultaneously. This initiative is poised to significantly impact the scleroderma market by accelerating the development and approval of effective therapies through its collaborative and efficient clinical evaluation approach.

In October 2023, Amgen Inc., a U.S.-based biotechnology company, acquired Horizon Therapeutics plc for about $27.8 billion. This acquisition is intended to enhance Amgen's portfolio of first-in-class medicines for rare inflammatory diseases, align with its core strategy of providing innovative treatments, and utilize its biologics research and manufacturing capabilities to improve health outcomes for patients worldwide. Horizon Therapeutics plc is an Ireland-based biotechnology company that focuses on treating scleroderma through Fipaxalparant.

Major companies operating in the scleroderma market include Pfizer Inc., Johnson And Johnson Inc., F. Hoffmann-La Roche AG, Abbvie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., GSK plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Aspen Pharmacare Holdings Limited, Boehringer Ingelheim International GmbH, Principia Biopharma Corp, aTyr Pharma Inc., Cumberland Pharmaceuticals Inc., Kadmon Holdings Inc., Emerald Health Pharmaceuticals Inc., FibroGen Inc., Argentis Pharmaceuticals LLC, Corbus Pharmaceuticals Holdings Inc., H.A.C. Pharma

North America was the largest region in the scleroderma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the scleroderma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the scleroderma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The scleroderma market consists of revenues earned by entities by providing dilation of blood vessels, immunosuppressants, relieving pain, and reducing infection. The market value includes the value of related goods sold by the service provider or included within the service offering. The scleroderma market also includes the sales of methotrexate, anti-thymocyte globulin, mycophenolate mofetil, and cyclophosphamide. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Scleroderma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on scleroderma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for scleroderma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The scleroderma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Medication; Surgery; Other Treatments
• 2) By Indication: Systemic Scleroderma; Localized Scleroderma
• 3) By End User: Hospital; Pharmaceutical Stores; Other End Users
• Subsegments:
• 1) By Medication: Immunosuppressants; Antifibrotic Agents; Vasodilators; Corticosteroids; Pain Relievers
• 2) By Surgery: Lung Transplantation; Other Surgical Interventions
• 3) By Other Treatments: Physical Therapy; Occupational Therapy; Lifestyle Modifications; Alternative Therapies
• Companies Mentioned: Pfizer Inc.; Johnson And Johnson Inc.; F. Hoffmann-La Roche AG; Abbvie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Scleroderma Market Characteristics

3. Scleroderma Market Trends And Strategies

4. Scleroderma Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Scleroderma Growth Analysis And Strategic Analysis Framework

• 5.1. Global Scleroderma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Scleroderma Market Growth Rate Analysis
• 5.4. Global Scleroderma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Scleroderma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Scleroderma Total Addressable Market (TAM)

6. Scleroderma Market Segmentation

• 6.1. Global Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Surgery
• Other Treatments
• 6.2. Global Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Systemic Scleroderma
• Localized Scleroderma
• 6.3. Global Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Pharmaceutical Stores
• Other End Users
• 6.4. Global Scleroderma Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunosuppressants
• Antifibrotic Agents
• Vasodilators
• Corticosteroids
• Pain Relievers
• 6.5. Global Scleroderma Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lung Transplantation
• Other Surgical Interventions
• 6.6. Global Scleroderma Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Physical Therapy
• Occupational Therapy
• Lifestyle Modifications
• Alternative Therapies

7. Scleroderma Market Regional And Country Analysis

• 7.1. Global Scleroderma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Scleroderma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Scleroderma Market

• 8.1. Asia-Pacific Scleroderma Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Scleroderma Market

• 9.1. China Scleroderma Market Overview
• 9.2. China Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Scleroderma Market

• 10.1. India Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Scleroderma Market

• 11.1. Japan Scleroderma Market Overview
• 11.2. Japan Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Scleroderma Market

• 12.1. Australia Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Scleroderma Market

• 13.1. Indonesia Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Scleroderma Market

• 14.1. South Korea Scleroderma Market Overview
• 14.2. South Korea Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Scleroderma Market

• 15.1. Western Europe Scleroderma Market Overview
• 15.2. Western Europe Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Scleroderma Market

• 16.1. UK Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Scleroderma Market

• 17.1. Germany Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Scleroderma Market

• 18.1. France Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Scleroderma Market

• 19.1. Italy Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Scleroderma Market

• 20.1. Spain Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Scleroderma Market

• 21.1. Eastern Europe Scleroderma Market Overview
• 21.2. Eastern Europe Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Scleroderma Market

• 22.1. Russia Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Scleroderma Market

• 23.1. North America Scleroderma Market Overview
• 23.2. North America Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Scleroderma Market

• 24.1. USA Scleroderma Market Overview
• 24.2. USA Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Scleroderma Market

• 25.1. Canada Scleroderma Market Overview
• 25.2. Canada Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Scleroderma Market

• 26.1. South America Scleroderma Market Overview
• 26.2. South America Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Scleroderma Market

• 27.1. Brazil Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Scleroderma Market

• 28.1. Middle East Scleroderma Market Overview
• 28.2. Middle East Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Scleroderma Market

• 29.1. Africa Scleroderma Market Overview
• 29.2. Africa Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Scleroderma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Scleroderma Market Competitive Landscape And Company Profiles

• 30.1. Scleroderma Market Competitive Landscape
• 30.2. Scleroderma Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson And Johnson Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Scleroderma Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Merck And Co. Inc.
• 31.3. Sanofi S.A.
• 31.4. Bristol-Myers Squibb Company
• 31.5. AstraZeneca plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Gilead Sciences Inc.
• 31.9. Amgen Inc.
• 31.10. GSK plc
• 31.11. Teva Pharmaceutical Industries Ltd.
• 31.12. Astellas Pharma Inc.
• 31.13. Aspen Pharmacare Holdings Limited
• 31.14. Boehringer Ingelheim International GmbH
• 31.15. Principia Biopharma Corp

32. Global Scleroderma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Scleroderma Market

34. Recent Developments In The Scleroderma Market

35. Scleroderma Market High Potential Countries, Segments and Strategies

• 35.1 Scleroderma Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Scleroderma Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Scleroderma Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer